Regen BioPharma Inc (RGBP)

[tw0122]

Dated: July 2, 2021 By: /s/ David Koos

KCL Therapeutics, Inc. (“KCL”) , a wholly owned subsidiary Regen Biopharma Inc. ( the “Company”), was informed by the United States Patent and Trademark Office ( USPTO) that patent protection shall be granted to KCL with regard to “METHODS AND MEANS OF GENERATING IL-17 ASSOCIATED ANTITUMOR EFFECTOR CELLS BY INHIBITION OF NR2F6 INHIBITION “( “Invention”).

The Invention pertains to stimulation of immunity to cancer antigens through augmentation of NR2F6 inhibition to augment T-cell activation.

The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.

2



SIGNATURE





REGEN BIOPHARMA, INC.

Dated: July 2, 2021 By: /s/ David Koos